To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...

Why Tiny Downloads Matter Again Modern web games can be massive, but the fastest experiences still start with a small ...

Best solar generator: Bluetti Elite 200 V2 Portable Power Station Best large-capacity solar generator: Anker F3000 Portable Power Station A backup power supply is essential when it comes to natural ...

Looking for ways to make some extra money this year? We've compiled a list of different passive income ideas to spark inspiration, including investing, real estate and a few niche options, like ...

This program is created solely for educational purposes. Any misuse of this program for illegal activities is not condoned and is beyond the responsibility of the creator. Contributions are welcome!

Digital retail finance, personal finance and payments industry which offers access to point of sale credit and digital payment services, connecting customers with its network of merchants and offers ...

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year. 2025 was a slow year for IPOs, with ...

Note: The major version of this plugin follows the major version of Capacitor. Use the version that matches your Capacitor installation (e.g., plugin v8 for Capacitor 8). Only the latest major version ...

Generate is indicative of a more mature startup that may have a better chance of succeeding in today’s markets. Industry IPOs peaked in 2021, resulting in a flood of companies whose early science didn ...